NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 23 min ago

Updated Process for Submission of Federal Financial Reports for Closed Payment Management System Subaccounts

Tue, 2021-06-01 03:39
Notice NOT-OD-21-128 from the NIH Guide for Grants and Contracts

Notice of Change to the Instructions for Appendices in PAR-21-147 "Maximizing Access to Research Careers (T34)"

Fri, 2021-05-28 13:55
Notice NOT-GM-21-048 from the NIH Guide for Grants and Contracts

Notice of Change to the Instructions for Appendices in PAR-19-299 "Bridges to the Baccalaureate Research Training Program (T34)"

Fri, 2021-05-28 13:47
Notice NOT-GM-21-042 from the NIH Guide for Grants and Contracts

NIA Predoctoral Fellowship Award to Promote Diversity in Translational Research for AD/ADRD (F31)

Fri, 2021-05-28 13:23
Funding Opportunity PAR-21-218 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This initiative will emphasize the development of skills in data science and drug discovery and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). It will support research training of promising predoctoral candidates from diverse backgrounds to help them gain critical translational skills in data science and drug discovery. The long-term goal of this program is to develop a diverse translational workforce that can effectively participate in and/or lead a team-science, precision medicine approach to AD/ADRD treatment, prevention, early detection, and disease management and care.

NIA Postdoctoral Fellowship Award to Promote Diversity in Translational Research for AD/ADRD (F32 Clinical Trial Not Allowed)

Fri, 2021-05-28 13:23
Funding Opportunity PAR-21-217 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This initiative will emphasize the development of skills in data science and drug discovery, and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). It will support research training of promising postdoctoral candidates from diverse backgrounds to help them gain critical translational skills in data science and drug discovery. The long-term goal of this program is to develop a diverse translational workforce that can effectively participate in and/or lead a team-science, precision medicine approach to AD/ADRD treatment, prevention, early detection, and disease management and care.

NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)

Fri, 2021-05-28 13:23
Funding Opportunity PAR-21-220 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This initiative will emphasize the development of skills in data science and drug discovery, and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). This initiative will support early career, independent investigators from diverse backgrounds to gain critical translational skills in data science and drug discovery. The long-term goal of this program is to develop a diverse translational workforce that can effectively participate in and/or lead a team-science, precision medicine approach to AD/ADRD treatment, prevention, early detection, and disease management and care.

New Receipt Date and Change in Cost Match Requirement for Commercial Fishing Occupational Safety Training Project Grants (T03)

Thu, 2021-05-27 02:46
Notice NOT-OH-21-009 from the NIH Guide for Grants and Contracts

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed)

Wed, 2021-05-26 12:40
Funding Opportunity RFA-HL-22-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of of highly trained investigators from diverse backgrounds , including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from Institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (see RFA-HL-22-010).

Pages